| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.041 | 0.5 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.5 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.5 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.028 | 0.5 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | selumetinib:UNC0638 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |